Skip to content
10-Q

Quarterly Report

Inhibitor Therapeutics, Inc. INTI

0001493152-24-030381

← back to feed
Filed
Aug 6, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Aug 6, 2024 172.32M sh
Cash And Equivalents Q2 2024 · Jun 30, 2024 $7.1M
Cash And Equivalents Q2 2024 · Dec 31, 2023 $8.84M
Current Liabilities Q2 2024 · Jun 30, 2024 $35.53K
Current Liabilities Q2 2024 · Dec 31, 2023 $665.16K
Total Liabilities Q2 2024 · Jun 30, 2024 $3.04M
Total Liabilities Q2 2024 · Dec 31, 2023 $3.67M
Current Assets Q2 2024 · Jun 30, 2024 $7.17M
Current Assets Q2 2024 · Dec 31, 2023 $8.95M
Total Assets Q2 2024 · Jun 30, 2024 $7.17M
Total Assets Q2 2024 · Dec 31, 2023 $8.95M
Shares Diluted Q2 2024 · Jun 30, 2023 171.97M sh
Shares Diluted Q2 2024 · Jun 30, 2023 171.88M sh
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$1.44M
Stockholders Equity Q2 2024 · Jun 30, 2023 $7.11M
Stockholders Equity Q2 2024 · Mar 31, 2023 $7.76M
Stockholders Equity Q2 2024 · Dec 31, 2022 $8.3M
Eps Diluted Q2 2024 · Jun 30, 2023 $0.00
Eps Diluted Q2 2024 · Jun 30, 2023 −$0.01
Eps Basic Q2 2024 · Jun 30, 2023 $0.00
Eps Basic Q2 2024 · Jun 30, 2023 −$0.01
Sga Expense Q2 2024 · Jun 30, 2023 $508.47K
Sga Expense Q2 2024 · Jun 30, 2023 $936.79K
Rd Expense Q2 2024 · Jun 30, 2023 $233.99K
Rd Expense Q2 2024 · Jun 30, 2023 $435.39K
Net Income Q2 2024 · Jun 30, 2023 −$654.52K
Net Income Q2 2024 · Jun 30, 2023 −$1.19M
Net Income Q2 2024 · Mar 31, 2023 −$539.6K
Operating Income Q2 2024 · Jun 30, 2023 −$742.46K
Operating Income Q2 2024 · Jun 30, 2023 −$1.37M